Tear lipocalin in muteins binding IL-4 R alpha

US8986951B2 · kind B2 · utility

Assignee

• Pieris AG · DE

Inventors

• Andreas Hohlbaum · Paunzhausen, DE
• Alexandra Baehre · Farum, DK
• Gabriele Matschiner · Munich, DE
• Stefan Trentmann · Freising, DE
• Klaus Kirchfeld · Petershausen, DE
• Hans-Juergen Christian · Moosburg an der Isar, DE

Key dates

• Filing date: Jun 8, 2011
• Grant date: Mar 24, 2015
• Expiry date: Jun 8, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.